Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz: An Open-Label, Randomized Controlled Trial

被引:7
|
作者
Boontanondha, Patawee [1 ]
Nimitphong, Hataikarn [1 ]
Musikarat, Suchawadee [2 ]
Ragkho, Aschara [3 ]
Kiertiburanakul, Sasisopin [1 ]
机构
[1] Mahidol Univ, Fac Med Ramathibodi Hosp, Dept Med, Bangkok 10400, Thailand
[2] Mahidol Univ, Fac Med, Dept Diagnost & Therapeut Radiol, Ramathibodi Hosp, Bangkok 10400, Thailand
[3] Mahidol Univ, Fac Med, Dept Pathol, Ramathibodi Hosp, Bangkok 10400, Thailand
关键词
Bone loss; bone mineral density; calcium; HIV; tenofovir disoproxil fumarate; vitamin D; C VIRUS COINFECTION; ANTIRETROVIRAL THERAPY; MINERAL DENSITY; D DEFICIENCY; ABACAVIR-LAMIVUDINE; RISK-FACTORS; ADULTS; FUMARATE; FRACTURES; EFAVIRENZ;
D O I
10.2174/1570162X18666200106150806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Antiretroviral therapy (ART), especially with tenofovir disoproxil fumarate (TDF), has been associated with accelerated bone turnover and leads to significant bone loss. Objective: We aimed to determine the effect of vitamin D-2 and calcium on bone mineral density (BMD) in HIV-infected patients receiving TDF/emtricitabine (FTC)/efavirenz (EFV). Methods: A prospective, open-label, randomized controlled study was conducted. Eligible patients were ART naive HIV individuals who initiated TDF/FTC/EFV. The study group received supplementation with vitamin D-2 and calcium carbonate, whereas the control group was administered only ART. The primary outcome was the percentage change in total hip BMD at week 24 compared with baseline. Results: A total of 18 patients were randomized (9 in each group). The mean (standard deviation; SD) total hip BMD significantly decreased from baseline in both groups, from 0.96 (0.14) g/cm(2) to 0.93 (0.13) g/cm(2) in the study group (p = 0.006) and from 0.87 (0.11) g/cm(2) to 0.84 (0.11) g/cm(2) in the control group (p = 0.004). The mean (SD) lumbar spine BMD significantly decreased from baseline in both groups, from 1.00 (0.13) g/cm(2) to 0.97 (0.13) g/cm(2) (p-0.004) in the study group and from 0.90 (0.09) g/cm(3) to 0.86 (0.08) g/cm(2) in the control group (p = 0.006). At week 24, the mean (SD) lumbar spine BMD was significantly greater in the study group than in the control group (p = 0.042). However, there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups. No adverse events were reported. In conclusion, as early as 24 weeks after TDF initiation, a significant decline in BMD was detected. Conclusion: Vitamin D-2 and calcium supplements should be considered for HIV-infected patients receiving TDF/FTC/EFV in a resource-limited setting where there are limited ART options
引用
收藏
页码:52 / 62
页数:11
相关论文
共 36 条
  • [21] Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
    Kityo, Cissy
    Hagins, Debbie
    Koenig, Ellen
    Avihingsanon, Anchalee
    Chetchotisakd, Ploenchan
    Supparatpinyo, Khuanchai
    Gankina, Natalya
    Pokrovsky, Vadim
    Voronin, Evgeny
    Stephens, Jeffrey L.
    DeJesus, Edwin
    Wang, Hui
    Acosta, Rima K.
    Cao, Huyen
    Quirk, Erin
    Martin, Hal
    Makadzange, Tariro
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (03) : 321 - 328
  • [22] A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naive patients
    Bracchi, Margherita
    Pagani, Nicole
    Dalla Pria, Alessia
    Milinkovic, Ana
    Nwokolo, Nneka
    Thomas, Lervina
    Mandalia, Sundhyia
    Boffito, Marta
    Moyle, Graeme
    HIV RESEARCH & CLINICAL PRACTICE, 2021, 22 (05) : 128 - 139
  • [23] Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial
    Andersson, Lars-Magnus
    Vesterbacka, Jan
    Blaxhult, Anders
    Flamholc, Leo
    Nilsson, Staffan
    Ormaasen, Vidar
    Sonnerborg, Anders
    Gisslen, Magnus
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2013, 45 (07) : 543 - 551
  • [24] Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
    Pozniak, Anton
    Arribas, Jose R.
    Gathe, Joseph
    Gupta, Samir K.
    Post, Frank A.
    Bloch, Mark
    Avihingsanon, Anchalee
    Crofoot, Gordon
    Benson, Paul
    Lichtenstein, Kenneth
    Ramgopal, Moti
    Chetchotisakd, Ploenchan
    Custodio, Joseph M.
    Abram, Michael E.
    Wei, Xuelian
    Cheng, Andrew
    McCallister, Scott
    SenGupta, Devi
    Fordyce, Marshall W.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (05) : 530 - 537
  • [25] Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial
    Pablo Rojo
    Cinta Moraleda
    Alfredo Tagarro
    Sara Domínguez-Rodríguez
    Lola Madrid Castillo
    Luis Manuel Prieto Tato
    Aranzazu Sancho López
    Lilit Manukyan
    Olivier Marcy
    Valeriane Leroy
    Alessandra Nardone
    David Burger
    Quique Bassat
    Matthew Bates
    Raoul Moh
    Pui-Ying Iroh Tam
    Tisungane Mvalo
    Justina Magallhaes
    W. Chris Buck
    Jahit Sacarlal
    Victor Musiime
    Chishala Chabala
    Hilda Angela Mujuru
    Trials, 23
  • [26] Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
    Gaur, Aditya H.
    Kizito, Hilda
    Prasitsueubsai, Wasana
    Rakhmanina, Natella
    Rassool, Mohammed
    Chakraborty, Rana
    Batra, Jagmohan
    Kosalaraksa, Pope
    Luesomboon, Wicharn
    Porter, Danielle
    Shao, Yongwu
    Myers, Michael
    Ting, Lillian
    SenGupta, Devi
    Quirk, Erin
    Rhee, Martin S.
    LANCET HIV, 2016, 3 (12): : E561 - E568
  • [27] The impact of vitamin D3 supplementation on muscle function among HIV-infected children and young adults: a randomized controlled trial
    Brown, J. C.
    Schall, J. I.
    Rutstein, R. M.
    Leonard, M. B.
    Zemel, B. S.
    Stallings, V. A.
    JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 2015, 15 (02) : 145 - 153
  • [28] A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients
    Menezes, C. N.
    Crowther, N. J.
    Duarte, R.
    Van Amsterdam, D.
    Evans, D.
    Dickens, C.
    Dix-Peek, T.
    Rassool, M.
    Prinsloo, A.
    Raal, F.
    Sanne, I.
    HIV MEDICINE, 2014, 15 (01) : 3 - 12
  • [29] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Raffi, Francois
    Pulido, Federico
    Gracia Mateo-Garcia, Maria
    Molina, Jean-Michel
    Ong, Edmund
    Shao, Yongwu
    Piontkowsky, David
    Das, Moupali
    McNicholl, Ian
    Haubrich, Richard
    LANCET HIV, 2019, 6 (10): : E655 - E666
  • [30] Efficacy of vitamin D3 supplementation in reducing incidence of pulmonary tuberculosis and mortality among HIV-infected Tanzanian adults initiating antiretroviral therapy: study protocol for a randomized controlled trial
    Sudfeld, Christopher R.
    Mugusi, Ferdinand
    Aboud, Said
    Nagu, Tumaini J.
    Wang, Molin
    Fawzi, Wafaie W.
    TRIALS, 2017, 18